Abbisko Cayman Limited announced that Dr. Yu Hongping, an executive Director, has been appointed as one of the joint company secretaries of the Company (the "Joint Company Secretary") with effect from April 29, 2024, and the company secretary of the Company, Ms. Chan Yin Wah, will continue to serve as the other Joint Company Secretary. Dr. Yu, aged 56, is a co-founder of the Group. Dr. Yu founded the Group on April 12, 2016 and was appointed as a Director and Senior Vice President, Chemistry on March 28, 2018.

Dr. Yu was designated as an executive Director on June 10, 2021 and was re-designated as Chief Scientific Officer in March, 2022. Dr. Yu worked as a senior research chemist at the Merck Frosst Centre for Therapeutic Research from October 2002 to April 2007, a pharmaceutical company engaged in the development, manufacture and marketing of pharmaceutical drugs, vaccines and animal-health products. From April 2007 to February 2012, Dr. Yu served as a Senior Research Investigator I at Novartis Institutes for BioMedical Research Co.

Ltd., a pharmaceutical company engaged in the development, manufacture and marketing of branded and generic prescription drugs, APIs, biosimilars and ophthalmic products. From October 2012 to February 2016, Dr. Yu served as the deputy General Manager of medicinal chemistry at Shanghai Hansoh BioMedical Co. Ltd. Dr. Yu has served as a Director at Abbisko Hong Kong since April 2018 and as a Director at Abbisko Shanghai since April 2016, both of which are wholly-owned subsidiaries of the cience from Tsinghua University in the PRC in July 1991 and March 1994, respectively.

He obtained his Doctoral degree in chemistry from the University of British Columbia in Canada in November 2000 and was a postdoctoral research fellow at that university between July 2001 and September 2002.